A general practitioner receiving an imaging report pre-written by an AI, a patient conducting part of their clinical trial from home, a medical algorithm monitored post-market like a drug: these situations, once marginal two years ago, now structure the daily life of the healthcare system.
The health trends that matter in 2026 are no longer about technological promise. They are changing practices, regulatory obligations, and the way we access care.
Transparency obligations on medical AI: what applies since August 2026
Since August 2, 2026, users must be informed when interacting with an AI. This obligation also applies to content generated or manipulated by an algorithm, which must be identifiable. We are no longer talking about a theoretical debate on the ethics of artificial intelligence, but about a concrete regulatory constraint affecting medical software, health chatbots, and diagnostic support tools.
The European compliance timeline for medical AI has been postponed, but these transparency obligations towards the user have indeed come into effect. For healthcare professionals in practices or institutions, this means ensuring that each digital tool used clearly displays its algorithmic nature.
The HAS, the CNIL, and healthcare institutions are simultaneously strengthening practical oversight. Recommendations focus on human supervision, traceability of algorithmic decisions, training for caregivers, and data governance. Following the health news on Pharmactuelle helps keep informed about the evolution of these regulatory frameworks over the months.
Algorithmovigilance: monitoring algorithms like drugs
We know about pharmacovigilance, the system that tracks adverse effects of a drug after its marketing. French studies propose applying the same principle to medical algorithms. The concept is called algorithmovigilance, and it addresses a concrete problem.
An algorithm trained on 2023 data can drift in 2026 if clinical practices, populations, or data formats have changed. Without continuous monitoring, no one detects this drift before it affects patients.
Algorithmovigilance provides for structured post-marketing monitoring:
- Detection of performance declines related to changes in input data or patient profiles
- Reporting of aberrant decisions or emerging biases, modeled after adverse effect reports
- Periodic reevaluation of models by clinical and technical teams, not just by the software publisher
This is not yet a mandatory regulatory framework, but the approach aligns with the logic of the European regulation on AI. Monitoring an algorithm after it goes live becomes as logical as monitoring a drug.
Decentralized clinical trials: research goes beyond the hospital walls
Participating in a clinical trial previously required regular visits to a hospital center, sometimes several hours away. This constraint effectively excluded some patients, particularly in rural areas or those with reduced mobility.
Clinical trials can now be organized more at home and in communities. We are talking about decentralized trials, where some visits, sample collections, or follow-ups are done remotely or through local professionals.
For patients, the change is tangible. Fewer trips, fewer lost days, and potentially expanded access to clinical research for areas far from university hospitals.
For trial sponsors, it is also a recruitment lever. Several teams observe better adherence when the protocol adapts to the patient’s living environment.
What this changes for data tracking
Decentralizing trials does not mean loosening control. Connected devices and digital platforms ensure real-time data collection. Traceability remains a prerequisite, and sponsors must guarantee that data collected at home is as reliable as that collected in the hospital.
Generative AI in practice: report writing and diagnostic assistance
Generative AI is no longer limited to consumer chatbots. It is integrated into medical software used in both community and hospital settings. The most concrete use in 2026: automated writing of medical reports from an audio recording of a consultation.
Time savings are the primary argument put forward by practitioners who use it. A general practitioner dictating their notes during the consultation receives a structured document in seconds, instead of spending time entering data after the day of care.
- Automatic transcription and structuring of clinical exchanges
- Proposing diagnostic codes consistent with the content of the consultation
- Assistance in personalizing referral letters to specialists
The tool remains an assistant. The final validation of the report belongs to the physician, in accordance with recommendations for human supervision. The goal is not to replace the clinician, but to reduce the administrative burden on teams already under pressure.
Training caregivers in digital tools
Integrating these tools requires that professionals know how to use them and understand their limitations. Current recommendations emphasize training on the principles of AI operation, not just on the software interface. A caregiver who does not understand how an algorithm produces a suggestion cannot exercise the supervision required by the regulatory framework.
The health trends of 2026 share a common thread: the transition from experimental technology to regulated tools. Algorithmovigilance structures monitoring, the decentralization of trials rethinks access to research, and generative AI transforms daily document management. What differentiates this period from previous ones is that the regulatory framework is advancing at the same pace as the tools, not five years behind.
